Track Stereotaxis, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Stereotaxis, Inc. STXS · Stock Open Stereotaxis, Inc. in new tab

0.8400 USD
EPS
-0.24
P/B
3.98
ROE
-117.39
Beta
1.40
Target Price
2.67 USD
Loading chart...
Key Metrics
Earnings dateMarch 8, 2027
EPS-0.24
Book Value0.21
Price to Book3.98
Debt/Equity29.81
% Insiders15.476%
Growth
Revenue Growth0.20%
Estimates
Forward P/E-4.96
Forward EPS-0.17
Target Mean Price2.67

DCF valuation

Model fair value for Stereotaxis, Inc. (STXS)
Result
Sign in to run the valuation for STXS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus Strong buy · mean target 2.67 USD (low 2.00, high 3.00) · as of 14 Nov 2026
Low 2.00
Mean 2.67
High 3.00
Price 0.8400
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Stereotaxis, Inc. Logo Stereotaxis, Inc. Analysis (STXS)

United States Health Care Official Website Stock

Is Stereotaxis, Inc. a good investment? Stereotaxis, Inc. (STXS) is currently trading at 0.8400 USD. Market analysts have a consensus price target of 2.67 USD. This suggests a potential upside from current levels.

Earnings Schedule: Stereotaxis, Inc. is expected to release its next earnings report on March 8, 2027. The market consensus estimate for Forward EPS is -0.17.

Investor FAQ

Does Stereotaxis, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Stereotaxis, Inc.?

Stereotaxis, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 8, 2027. The company currently has a trailing EPS of -0.24.

Company Profile

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.

Exchange Ticker
ASE (United States) STXS
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
July 11, 2012 1:10
Nov. 4, 2013 1.1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion